Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Clinical Lung Cancer|June 25, 2017
Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung CancerGavitt A Woodard, Sue X Wang, Johannes R Kratz, et al.
Biorxiv : the Preprint Server for Biology|November 19, 2025
CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancerBeatrice Gini, Philippe Gui, Wei Wu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2025
Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung CancerKoji Fukuda, Shigeki Nanjo, Shinji Takeuchi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2023
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief ReportDong-Wan Kim, Sang-We Kim, D Ross Camidge, et al.
Cancer Research|December 13, 2018
Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion ProteinsDana S Neel, David V Allegakoen, Victor Olivas, et al.
JAMA Network Open|September 30, 2020
Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical TrialSusan Y Wu, Ann A Lazar, Matthew A Gubens, et al.
Future Oncology (London, England)|November 8, 2024
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib studyLyudmila Bazhenova, Dong-Wan Kim, Byoung Chul Cho, et al.
Nature Genetics|November 22, 2016
Inactivation of Capicua drives cancer metastasisRoss A Okimoto, Frank Breitenbuecher, Victor R Olivas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2018
Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung CancerCaroline E McCoach, Collin M Blakely, Kimberly C Banks, et al.
JTO Clinical and Research Reports|March 7, 2023
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter StudyJingran Ji, Jacqueline V Aredo, Andrew Piper-Vallillo, et al.
Pageof 6